Impact of Xerosis in Patients With Cancer Receiving Epidermal Growth Factor Receptor or Mitogen-Activated Protein Kinase Inhibitors: ATIXI, A Non-Interventional, Prospective, Pilot Study

Pietro Quaglino; Giuseppe Argenziano; Emi Dika; Michela Starace; Simone Amabile; Paolo Fava; Elvira Moscarella; Bianca Maria Piraccini; Alain Delarue; Olivia Dialla; Fabienne Zumaglini; Giampiero Girolomoni

doi:10.5826/dpc.1404a259

Impact of Xerosis in Patients With Cancer Receiving Epidermal Growth Factor Receptor or Mitogen-Activated Protein Kinase Inhibitors: ATIXI, A Non-Interventional, Prospective, Pilot Study

Authors

Pietro Quaglino Dermatologic Clinic, Department of Medical Sciences, University of Turin, Turin, Italy
Giuseppe Argenziano Dermatology Unit, Department of Mental and Physical Health and Preventive Medicine, University of Campania Luigi Vanvitelli Naples, Naples, Italy
Emi Dika Oncologic Dermatology Unit , IRCCS Azienda Ospedaliero-Universitaria di Bologna, Italy Department of Medical and Surgical Sciences , Alma Mater Studiorum University of Bologna, Italy
Michela Starace Department of Medical and Surgical Sciences , Alma Mater Studiorum University of Bologna, Italy Dermatology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico S. Orsola-Malpighi, Bologna, Italy
Simone Amabile Dermatologic Clinic, Department of Medical Sciences, University of Turin, Turin, Italy
Paolo Fava Dermatologic Clinic, Department of Medical Sciences, University of Turin, Turin, Italy
Elvira Moscarella Dermatology Unit, Department of Mental and Physical Health and Preventive Medicine, University of Campania Luigi Vanvitelli Naples, Naples, Italy
Bianca Maria Piraccini Department of Medical and Surgical Sciences , Alma Mater Studiorum University of Bologna, Italy Dermatology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico S. Orsola-Malpighi, Bologna, Italy
Alain Delarue Pierre Fabre, Lavaur, France
Olivia Dialla Pierre Fabre, Boulogne-Billancourt, France
Fabienne Zumaglini Pierre Fabre, Lavaur, France
Giampiero Girolomoni Department of Medicine, Section of Dermatology, University of Verona, Verona, Italy

Keywords:

adverse effects, anti-cancer treatments, cutaneous toxicity, EGFR inhibitors, MEK inhibitors, xerosis

References

Lacouture M, Sibaud V. Toxic side effects of targeted therapies and immunotherapies affecting the skin, oral mucosa, hair, and nails. Am J Clin Dermatol. 2018;19(Suppl 1):31–9. DOI: 10.1007/s40257-018-0384-3.

Robert C, Soria JC, Spatz A, et al. Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet Oncol. 2005;6(7):491-500. DOI:10.1016/S1470-2045(05)70243-6.

Valentine J, Belum VR, Duran J, et al. Incidence and risk of xerosis with targeted anticancer therapies. J Am Acad Dermatol. 2015;72(4):656-667. DOI:10.1016/j.jaad.2014.12.010.

Lee J, Lim J, Park JS, et al. The Impact of Skin Problems on the Quality of Life in Patients Treated with Anticancer Agents: A Cross-Sectional Study. Cancer Res Treat. 2018;50(4):1186-1193. DOI:10.4143/crt.2017.435.

Lacouture ME. Mechanisms of cutaneous toxicities to EGFR inhibitors. Nat Rev Cancer. 2006;6(10):803-812. DOI:10.1038/nrc1970.

Pastore S, Lulli D, Girolomoni G. Epidermal growth factor receptor signalling in keratinocyte biology: implications for skin toxicity of tyrosine kinase inhibitors. Arch Toxicol. 2014;88(6):1189-1203. DOI:10.1007/s00204-014-1244-4.